{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":1682,"total_is_capped":false,"direct_labels_cover":5,"predictions_cover":1682,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"fe77064d49b2","filters":{"topic":"Pharmaceutical Economics and Policy"}},"results":[{"id":"W2158310952","doi":"10.1016/s0140-6736(02)09096-7","title":"Drug development for neglected diseases: a deficient market and a public-health policy failure","year":2002,"lang":"en","type":"review","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":882,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"","keywords":"Incentive; Private sector; Public health; Pharmaceutical industry; Drug development; Developing country; Business; Market failure; Medicine; Disease; Neglected tropical diseases; Agency (philosophy); Economic growth; Public economics; Drug; Economics; Pharmacology","retraction":null,"screen_n_in":null,"score":{"opus":0.157997367515106,"gpt":0.3480298722680117,"spread":0.1900325047529057,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006510061,0.0003948772,0.002312477,0.0003377644,0.0002944,0.0002946695,0.0006980029,0.0001296148,0.0002684645],"category_scores_gemma":[0.0002702012,0.0003170192,0.0002869411,0.0003830628,0.00008844235,0.000079262,0.0002052324,0.0003169376,0.0002262663],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004654626,"about_ca_system_score_gemma":0.0004345867,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007767534,"about_ca_topic_score_gemma":0.00005709513,"domain_scores_codex":[0.9973809,0.00007692067,0.001028174,0.0005606971,0.00003298399,0.0009203433],"domain_scores_gemma":[0.9979887,0.0002814888,0.0007416889,0.0006108446,0.00002006515,0.0003572199],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000007377202,0.00009412874,0.00003561833,0.006846917,0.0002628241,5.592302e-7,0.0004449814,3.988793e-7,1.851938e-9,0.1278339,0.3012603,0.563213],"study_design_scores_gemma":[0.0005107265,0.00001477842,0.00005982597,0.0003870541,0.00002959497,0.000008376984,0.00001006133,0.0002852016,7.255402e-9,0.00349082,0.9948484,0.0003551278],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000008490049,0.9668686,0.000119423,0.02277091,0.0001558864,0.001230193,0.003152366,0.00005131927,0.005642811],"genre_scores_gemma":[0.00005507301,0.9912305,0.0005121932,0.005021717,0.001140902,0.0004760065,0.0001583295,0.00006846124,0.001336778],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6935881,"threshold_uncertainty_score":0.9999282,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2052972684","doi":"10.1016/j.mib.2003.08.003","title":"Why is big Pharma getting out of antibacterial drug discovery?","year":2003,"lang":"en","type":"review","venue":"Current Opinion in Microbiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":501,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Drug discovery; Bureaucracy; Clinical trial; Drug development; Drug; Biology; Investment (military); Business; Process (computing); Intensive care medicine; Biotechnology; Pharmacology; Bioinformatics; Medicine; Political science; Law; Computer science","retraction":null,"screen_n_in":null,"score":{"opus":0.184830175105148,"gpt":0.3916683300344007,"spread":0.2068381549292527,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006232254,0.0004885378,0.002532986,0.0006131058,0.00004288015,0.00005754605,0.0005663772,0.0003424662,0.0004369193],"category_scores_gemma":[0.00005287594,0.0005229187,0.000633129,0.0002388336,0.0001669113,0.0001275854,0.0002291545,0.0006169641,0.0005033878],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001834157,"about_ca_system_score_gemma":0.0001220844,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002825121,"about_ca_topic_score_gemma":0.000003049945,"domain_scores_codex":[0.9962846,0.0001418185,0.002179059,0.0008057075,0.00001144399,0.0005773384],"domain_scores_gemma":[0.9978894,0.0001449361,0.00144378,0.0004133134,0.0000193087,0.00008924671],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003527392,0.0007472128,0.0006011392,0.03717294,0.00049663,0.000001173718,0.0005772609,0.000002417197,0.00005775901,0.05645754,0.2076456,0.696205],"study_design_scores_gemma":[0.0005671842,0.0000178409,0.000001869324,0.001846148,0.00002414501,0.00000840243,0.000002306522,0.000006245468,0.00001202875,0.0007635523,0.9962391,0.000511229],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00009254282,0.9640946,0.00006239012,0.0001994119,0.02963829,0.000504968,0.004805419,0.00001090999,0.0005915166],"genre_scores_gemma":[0.00002238332,0.9975467,0.0000395805,0.0003484437,0.001065292,0.00003934803,0.000766333,0.00005606199,0.0001158263],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7885934,"threshold_uncertainty_score":0.9997222,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1970577443","doi":"10.1016/j.healthpol.2010.12.002","title":"The cost of drug development: A systematic review","year":2011,"lang":"en","type":"review","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":497,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"York University; University of Toronto; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Audit; Citation; Actuarial science; Medicine; Cash; Transparency (behavior); Confidentiality; Accounting; Business; Computer science; Finance; Library science","retraction":null,"screen_n_in":null,"score":{"opus":0.2564027925749183,"gpt":0.4341284522402911,"spread":0.1777256596653727,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003345347,0.0004077766,0.004592543,0.0003510433,0.0002481909,0.0000377295,0.0009144416,0.0001410944,0.0001020079],"category_scores_gemma":[0.0005781482,0.0003068283,0.0005776665,0.0005100807,0.00009888268,0.000056778,0.0001688713,0.0004099669,0.002776134],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006073146,"about_ca_system_score_gemma":0.001587059,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006620385,"about_ca_topic_score_gemma":0.00006349517,"domain_scores_codex":[0.9944311,0.0001878854,0.004223161,0.0003973267,0.00003617679,0.0007243366],"domain_scores_gemma":[0.9944353,0.0003682116,0.003924401,0.0008925115,0.00003095144,0.0003486464],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","study_design_scores_codex":[3.67314e-7,0.00001725398,2.728202e-7,0.6655061,0.0001040063,1.532663e-7,0.0001285677,9.538913e-9,3.427033e-11,0.2624068,0.005287895,0.06654864],"study_design_scores_gemma":[0.00006235606,0.000007543535,5.256891e-7,0.1824499,0.00005688303,0.000008656494,0.000001766391,0.000001872963,1.571266e-8,0.001515305,0.8156887,0.0002064604],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[2.569364e-8,0.9772317,0.00001219884,0.002036114,0.0002426717,0.003436685,0.0003429716,0.00002050801,0.01667715],"genre_scores_gemma":[0.000001136655,0.9902976,0.00004375054,0.006805884,0.0001833193,0.0008004837,0.00003382401,0.00006879601,0.001765176],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8104008,"threshold_uncertainty_score":0.9999384,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1989247444","doi":"10.1001/jama.2008.758","title":"Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease","year":2008,"lang":"en","type":"review","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":430,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Institute on Aging; Agency for Healthcare Research and Quality","keywords":"Medicine; Randomized controlled trial; Jadad scale; Medical prescription; Bioequivalence; Generic drug; Brand names; Clinical trial; MEDLINE; Context (archaeology); Drug; Internal medicine; Pharmacology; Advertising","retraction":null,"screen_n_in":null,"score":{"opus":0.1798119531198471,"gpt":0.3666103435232169,"spread":0.1867983904033698,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009745704,0.0003156995,0.003097668,0.0003094595,0.00003164321,0.0000403048,0.000383494,0.0003245779,0.00009286767],"category_scores_gemma":[0.0002576729,0.0003390399,0.001379689,0.0002496177,0.0002039475,0.0001362219,0.0001932921,0.0004641732,0.0002149114],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009005301,"about_ca_system_score_gemma":0.0001423233,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001050808,"about_ca_topic_score_gemma":0.000001316318,"domain_scores_codex":[0.9969912,0.0001022299,0.001806297,0.0007079731,0.00004465065,0.000347648],"domain_scores_gemma":[0.9981278,0.0002828571,0.0005611567,0.0006986545,0.00001481666,0.0003147772],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001038934,0.00008509225,0.002440737,0.003496037,0.0004117227,0.00002333632,0.00004868265,0.00001530848,3.01849e-9,0.005384705,0.0003844774,0.9876995],"study_design_scores_gemma":[0.0008403142,0.00001699792,0.001323306,0.0006651851,0.0001103185,0.000007551377,0.000001243512,0.000427993,3.627042e-8,0.001286884,0.9949679,0.000352248],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001431012,0.9944,0.00002555107,0.00009458746,0.0002972899,0.000413778,0.0006072347,0.00001099257,0.002719501],"genre_scores_gemma":[0.001851611,0.9971995,0.00007382325,0.0002718638,0.000372261,0.00004646986,0.0000321008,0.00004833603,0.0001040623],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9945834,"threshold_uncertainty_score":0.9999062,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1777587551","doi":"10.1016/s0140-6736(15)00469-9","title":"Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":394,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Simon Fraser University; Université Laval; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Canadian Institutes of Health Research; International Development Research Centre; Heart and Stroke Foundation of Canada","keywords":"Pharmacy; Medicine; Environmental health; Disease; Middle income; Rural area; Socioeconomics; Business; Economics; Demographic economics; Family medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.08904064535655133,"gpt":0.2970635422064158,"spread":0.2080228968498645,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004747976,0.0001864981,0.001289504,0.0001450389,0.00006357153,0.0000514309,0.0005747137,0.00005111731,0.00001134427],"category_scores_gemma":[0.0007114963,0.0001122597,0.00009220497,0.0003636254,0.000457768,0.00022305,0.0004350839,0.0001689535,0.000001196698],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004815723,"about_ca_system_score_gemma":0.00002572618,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001766101,"about_ca_topic_score_gemma":0.0009820965,"domain_scores_codex":[0.9983882,0.0002595698,0.0005763113,0.0004965509,0.00006931196,0.0002100253],"domain_scores_gemma":[0.9967376,0.0006037784,0.0002310014,0.002232966,0.00003162364,0.0001630551],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002784185,0.00009765139,0.9959713,0.0001831968,0.0007229833,7.53051e-7,0.0005868992,0.0004015915,4.011831e-7,0.001593678,0.000008930417,0.0001541563],"study_design_scores_gemma":[0.001868477,0.000170053,0.9794902,0.00003928988,0.0003120336,4.033959e-7,0.00009833158,0.01405162,0.00000885907,0.003337428,0.0004991117,0.0001241717],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938862,0.002387902,0.000005787201,0.0006554763,0.00008591729,0.0005765268,0.002335313,0.000007533029,0.00005930808],"genre_scores_gemma":[0.9991928,0.0005129233,0.00000804343,0.0001633641,0.00007693163,0.00001449252,0.00001662297,0.00001068193,0.000004163733],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01648112,"threshold_uncertainty_score":0.4577816,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2770849724","doi":"10.3389/fonc.2017.00273","title":"Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics","year":2017,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":286,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Repurposing; Drug repositioning; Leverage (statistics); Clinical trial; Medicine; Cancer drugs; Drug development; Drug; Business; Approved drug; Alternative medicine; Government (linguistics); Pharmacology; Computer science; Engineering; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1036281468605397,"gpt":0.3817537428207261,"spread":0.2781255959601864,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001438379,0.0005300883,0.003357133,0.0009162436,0.0001776227,0.0001240886,0.0006416778,0.001033943,0.0001208554],"category_scores_gemma":[0.0001503925,0.0006380955,0.0003015566,0.0002030951,0.0003442111,0.0002674636,0.0003032978,0.001160379,0.00002812715],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001860641,"about_ca_system_score_gemma":0.0006954378,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002921671,"about_ca_topic_score_gemma":0.0002741956,"domain_scores_codex":[0.9964579,0.0001208472,0.001585754,0.001011571,0.00003775546,0.0007861481],"domain_scores_gemma":[0.9975718,0.0002093826,0.00148578,0.0005672807,0.00001537788,0.0001503263],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000298815,0.00007009119,0.001077794,0.002351819,0.0001125358,0.00001827102,0.001719358,0.00000363307,2.124859e-7,0.006437789,0.001808082,0.9863705],"study_design_scores_gemma":[0.0009249436,0.0000456224,0.0001599018,0.001448187,0.00004973925,0.00001027164,0.00007319303,0.0008311559,8.613883e-7,0.01537373,0.9804485,0.000633901],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001719223,0.9782785,0.00003953914,0.0003293271,0.003157222,0.0008131068,0.0002447052,0.00001776806,0.01540058],"genre_scores_gemma":[0.0008506463,0.994565,0.0008082342,0.001389699,0.000552117,0.0003032986,0.00001750252,0.00009067983,0.001422812],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9857366,"threshold_uncertainty_score":0.999607,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2024556879","doi":"10.1086/467458","title":"Does Regulation Drive Out Competition in Pharmaceutical Markets?","year":2000,"lang":"en","type":"article","venue":"The Journal of Law and Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":242,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Competitor analysis; Competition (biology); Drug prices; Industrial organization; Business; Economics; Pharmacy; Public economics; Marketing","retraction":null,"screen_n_in":null,"score":{"opus":0.0416971653487621,"gpt":0.2816545989510505,"spread":0.2399574336022884,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001132945,0.0001085412,0.0003205888,0.00008617934,0.00007922149,0.00006314156,0.0001729077,0.00006650356,0.001456774],"category_scores_gemma":[0.00001165315,0.00007763297,0.00007657811,0.00003130376,0.000139187,0.0003529039,0.00002558499,0.0002327466,0.0001414802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009165813,"about_ca_system_score_gemma":0.00001385984,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004255965,"about_ca_topic_score_gemma":0.00008641439,"domain_scores_codex":[0.9988611,0.00003592557,0.0007715173,0.0001184158,0.00001302946,0.0002000436],"domain_scores_gemma":[0.9993306,0.0001278825,0.0002940921,0.0001265323,0.00001246342,0.0001084371],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00035092,0.00007819224,0.00345026,0.00001597701,0.00006286945,0.000002183907,0.0008976858,0.0009022894,0.00002757169,0.9879692,0.0002149122,0.006027994],"study_design_scores_gemma":[0.001795367,0.00006935588,0.01338334,0.00002355659,0.00002211495,0.00005504542,0.00005898893,0.01553403,0.0002799247,0.3410609,0.6274768,0.0002405569],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9151264,0.0006189212,0.00007348409,0.006145249,0.0003640337,0.00009399013,0.00004177985,0.000004239432,0.07753192],"genre_scores_gemma":[0.9880691,0.007967958,0.00008953652,0.003241496,0.0002728713,0.000001220217,0.000002080923,0.00001258238,0.0003431287],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6469082,"threshold_uncertainty_score":0.999456,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2077420003","doi":"10.1136/bmj.e4348","title":"Pharmaceutical research and development: what do we get for all that money?","year":2012,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":225,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"York University","funders":"","keywords":"Incentive; Mythology; Business; Economics; Market economy; Art; Literature","retraction":null,"screen_n_in":null,"score":{"opus":0.4040375696304965,"gpt":0.4486313239890954,"spread":0.04459375435859897,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002344495,0.0001394728,0.0002755667,0.0001962602,0.0001550543,0.0002532576,0.0001952315,0.0001167586,0.0004028885],"category_scores_gemma":[0.00008747407,0.0001558909,0.00005068904,0.00008203465,0.0001392582,0.0006689558,0.0001661684,0.000223742,0.001014284],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009734391,"about_ca_system_score_gemma":0.00002960177,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006970816,"about_ca_topic_score_gemma":0.000001880415,"domain_scores_codex":[0.9984062,0.00002010279,0.000429408,0.0003143091,0.00004177637,0.0007882128],"domain_scores_gemma":[0.9989944,0.0002672117,0.0000950297,0.0002074617,0.00002545467,0.0004104307],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001494293,0.0003656812,0.04035497,0.0001980907,0.000225874,0.000002188961,0.003063382,0.000003975508,0.00005234173,0.7756871,0.06249376,0.1174032],"study_design_scores_gemma":[0.0006807642,0.00002330128,0.001493577,0.00001676948,0.000003036563,0.000006533468,0.00012169,0.0006898945,0.0007101526,0.02808557,0.9679484,0.0002203025],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4770042,0.3070716,0.002811164,0.1368284,0.004226873,0.004155473,0.0004747716,0.0001567967,0.06727066],"genre_scores_gemma":[0.9703236,0.02029023,0.003220136,0.003581807,0.0009971269,0.0002907064,0.0000205449,0.00005234756,0.001223462],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9054546,"threshold_uncertainty_score":0.9997635,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4210321301","doi":"","title":"Classifying antibiotics in the WHO Essential Medicines List for optimal use-be AWaRe","year":2018,"lang":"en","type":"article","venue":"Archive ouverte UNIGE (University of Geneva)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":216,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Essential medicines; Economic shortage; Scopus; Antibiotic resistance; Business; Medicine; Antibiotics; Political science; Health care; MEDLINE; Biology; Law","retraction":null,"screen_n_in":null,"score":{"opus":0.07596587356098482,"gpt":0.2704283470410067,"spread":0.1944624734800218,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003192844,0.0001209483,0.0003135247,0.0002331489,0.0002457831,0.00003110362,0.0005193307,0.00006811378,0.0001465715],"category_scores_gemma":[0.00005246743,0.0001376195,0.0001381965,0.0001699384,0.0004249844,0.0002167006,0.0001325396,0.0001306538,0.00002761102],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004438431,"about_ca_system_score_gemma":0.00004167929,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007523512,"about_ca_topic_score_gemma":0.001808602,"domain_scores_codex":[0.9991351,0.00003030804,0.0002235668,0.0002839608,0.00003460954,0.0002924479],"domain_scores_gemma":[0.9992329,0.0001896091,0.0001884254,0.0002703315,0.00003803166,0.00008065869],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006582495,0.0004472844,0.08562774,0.0002413871,0.0004129051,0.00003912722,0.02888227,0.0004388683,0.001124865,0.7616755,0.1167759,0.003675959],"study_design_scores_gemma":[0.00361551,0.0004651979,0.05484497,0.00007179053,0.00006597081,0.000006559966,0.004812431,0.4116227,0.0004168967,0.01965409,0.5038033,0.0006205917],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9163474,0.0001084893,0.05964587,0.007255697,0.0003838626,0.0004335119,0.001111553,0.00001906021,0.0146945],"genre_scores_gemma":[0.9947363,0.0004780511,0.002453581,0.001715002,0.0001844977,1.562093e-7,0.00004234943,0.00001475743,0.0003752727],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7420214,"threshold_uncertainty_score":0.5611959,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2751849735","doi":"10.1016/s2468-2667(17)30141-x","title":"Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data","year":2017,"lang":"en","type":"article","venue":"The Lancet Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":214,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Hamilton Health Sciences; Université Laval; Simon Fraser University; Population Health Research Institute; McMaster University","funders":"Deanship of Scientific Research, King Saud University; Philippine Council for Health Research and Development; Canadian Institutes of Health Research; Servier; Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu; United Arab Emirates University; Universiti Kebangsaan Malaysia; Universiti Teknologi MARA; International Development Research Centre; Svenska Forskningsrådet Formas; Forskningsrådet för Arbetsliv och Socialvetenskap; Indian Council of Medical Research; North-West University; South Africa Netherlands research Programme on Alternatives in Development; Public Health Agency of Canada; AFA Försäkring; Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences; Universidad de La Frontera; Ministerstwo Edukacji i Nauki; GlaxoSmithKline; Vetenskapsrådet; Heart and Stroke Foundation of Canada; Boehringer Ingelheim; Ministry of Higher Education, Malaysia; AstraZeneca Canada; AstraZeneca","keywords":"Developing country; Medicine; Environmental health; Business; Economics; Economic growth","retraction":null,"screen_n_in":null,"score":{"opus":0.06005507458694665,"gpt":0.325043724570828,"spread":0.2649886499838813,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01445871,0.0002421622,0.001750731,0.0001616977,0.0004480567,0.0001984123,0.00148461,0.00009414111,0.00003104587],"category_scores_gemma":[0.00159612,0.000137534,0.00007181195,0.0002480243,0.001062609,0.0003572073,0.0006358422,0.0004058449,5.422724e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001651404,"about_ca_system_score_gemma":0.00008083442,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004534747,"about_ca_topic_score_gemma":0.003467321,"domain_scores_codex":[0.9971846,0.0005323993,0.00106917,0.0006452803,0.0001096407,0.0004589329],"domain_scores_gemma":[0.9942027,0.001395364,0.001120656,0.003052525,0.00004302709,0.0001856863],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000247146,0.000198142,0.9861721,0.0006672211,0.00153031,3.521542e-7,0.0009840464,0.00005001748,9.284018e-7,0.009895218,0.000007379095,0.0002471263],"study_design_scores_gemma":[0.00733894,0.0004386192,0.9745041,0.00006464826,0.0008719074,0.000001414014,0.00006026998,0.01437941,0.000006190643,0.00148372,0.0007158695,0.0001348832],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9733336,0.004634485,0.000005671026,0.01830043,0.0001325871,0.001436455,0.001943948,0.00001139043,0.0002014554],"genre_scores_gemma":[0.9980516,0.0009502337,0.00000684112,0.0007852823,0.0001255644,0.00004374294,0.000008101997,0.00001448096,0.00001413388],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02471805,"threshold_uncertainty_score":0.6855211,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2163707071","doi":"10.1377/hlthaff.w3.521","title":"Prices And Availability Of Pharmaceuticals: Evidence From Nine Countries","year":2003,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":206,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Liberian dollar; Pound (networking); Economics; Agricultural economics; International economics; Demographic economics; Business; Finance","retraction":null,"screen_n_in":null,"score":{"opus":0.1186151573046771,"gpt":0.3518014459299277,"spread":0.2331862886252506,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001323897,0.0001403762,0.0005108531,0.0000889951,0.00008340555,0.00003351042,0.0001355248,0.00006876539,0.001864791],"category_scores_gemma":[0.0004583094,0.0001574096,0.00005639809,0.0001276199,0.0002004456,0.0002267701,0.00004285512,0.0001550677,0.0002400247],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001116602,"about_ca_system_score_gemma":0.0001253485,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005828888,"about_ca_topic_score_gemma":0.00004449783,"domain_scores_codex":[0.9983166,0.00004498851,0.0008388676,0.0003973716,0.00003309695,0.0003690477],"domain_scores_gemma":[0.9985651,0.0004257576,0.0003919833,0.0002730615,0.00002635931,0.0003177351],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000100758,0.0001959594,0.2919455,0.0007173097,0.00008961341,0.000001521075,0.00185581,0.0000225524,0.00003718407,0.69498,0.008252259,0.001801495],"study_design_scores_gemma":[0.001525911,0.0002234295,0.04214816,0.000133722,0.00001566232,0.000005063163,0.0003116078,0.003097016,0.001558552,0.0776784,0.872771,0.0005314839],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8088152,0.1281533,0.0007829309,0.02315376,0.0006821301,0.0006987767,0.0009233128,0.0000638924,0.03672663],"genre_scores_gemma":[0.9822349,0.01403151,0.001325155,0.002234128,0.00005307948,0.00001417536,0.000003715842,0.0000140992,0.00008926853],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8645187,"threshold_uncertainty_score":0.9990476,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2889089805","doi":"10.1016/s2213-8587(18)30233-x","title":"Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study","year":2018,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":200,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; Simon Fraser University; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; Population Health Research Institute","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Medicine; Metformin; Pharmacy; Environmental health; Audit; Diabetes mellitus; Glibenclamide; Epidemiology; Family medicine; Business; Internal medicine; Accounting; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.04565561249153537,"gpt":0.3240000573649068,"spread":0.2783444448733714,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002958466,0.0003403561,0.001797273,0.00009165109,0.0002971315,0.00004926538,0.0004982794,0.0001420108,0.0001243531],"category_scores_gemma":[0.001501718,0.0002586508,0.0001180173,0.0001643091,0.002541566,0.0001451285,0.0004924671,0.000293125,0.0000264162],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000803325,"about_ca_system_score_gemma":0.00002262373,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000103443,"about_ca_topic_score_gemma":0.0001599292,"domain_scores_codex":[0.9964592,0.0001574132,0.00113103,0.0008033246,0.00004257387,0.001406397],"domain_scores_gemma":[0.9962965,0.002214541,0.0005322075,0.0006931321,0.0001170154,0.0001466437],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001451131,0.000136088,0.9530433,0.00029052,0.0002347779,5.533803e-7,0.0006209477,0.000001513982,0.00003738857,0.0452617,0.00004418257,0.0001838527],"study_design_scores_gemma":[0.002688664,0.001005288,0.8742131,0.00002962061,0.00004138175,0.000001621042,0.0001044205,0.0009638983,0.0008916795,0.1184605,0.001333787,0.000266086],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907181,0.001151904,0.00002590532,0.004990217,0.0004864762,0.00133118,0.0009994116,0.00005479664,0.0002420309],"genre_scores_gemma":[0.9972119,0.0003268996,0.0001945389,0.001217276,0.000694541,0.0003002277,0.000007280625,0.00002461655,0.00002276532],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07883029,"threshold_uncertainty_score":0.9999866,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1969868159","doi":"10.2190/4m3e-l0yf-w1td-ekg0","title":"Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence","year":2004,"lang":"en","type":"review","venue":"International Journal of Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":199,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"York University","funders":"","keywords":"Cost sharing; Medical prescription; Prescription drug; Subsidy; Drug; Health care; Prescription costs; Business; Medicine; Public economics; Environmental health; Actuarial science; Economic growth; Economics; Pharmacology; Nursing","retraction":null,"screen_n_in":null,"score":{"opus":0.1131953707533533,"gpt":0.4064047241796713,"spread":0.293209353426318,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003754219,0.0002752508,0.002554495,0.0005764037,0.00009082754,0.00008870882,0.0005377771,0.0000657675,0.00000618336],"category_scores_gemma":[0.0001108985,0.0002071835,0.0002336496,0.0002162309,0.00003385161,0.0005045577,0.0001009858,0.0004580749,0.000003556874],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007902818,"about_ca_system_score_gemma":0.0005111101,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01056011,"about_ca_topic_score_gemma":0.0009849998,"domain_scores_codex":[0.9950224,0.0005492647,0.003668869,0.0002880163,0.0001933204,0.0002781164],"domain_scores_gemma":[0.9906865,0.0006559519,0.008100194,0.0002453289,0.0001317018,0.0001802816],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.00001699684,0.0001373439,0.0009983419,0.9848536,0.0001291308,8.675328e-7,0.00086684,0.00005624284,1.774048e-8,0.00895297,0.00006796981,0.003919709],"study_design_scores_gemma":[0.0004935649,0.0001610624,0.004492421,0.9769756,0.00005066189,0.00001849018,0.00004817163,0.00009289875,4.496509e-7,0.002129677,0.01539826,0.0001386933],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002978373,0.9882308,0.000003767445,0.006356126,0.0006186442,0.001588858,0.0002111342,0.000003237429,0.000009107286],"genre_scores_gemma":[0.01155727,0.979368,0.00009937459,0.008832247,0.00006121893,0.00002937002,0.0000135895,0.00002353938,0.00001538114],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01533029,"threshold_uncertainty_score":0.9960287,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2147450289","doi":"10.1345/aph.1p389","title":"Physician Perceptions About Generic Drugs","year":2011,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":193,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Family medicine; Descriptive statistics; Likert scale; Generic drug; Logistic regression; Perception; Population; Quarter (Canadian coin); Health care; Environmental health; Drug; Internal medicine; Pharmacology; Psychology","retraction":null,"screen_n_in":null,"score":{"opus":0.2192757037191003,"gpt":0.3669874518227134,"spread":0.147711748103613,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002761954,0.0001594503,0.0003468278,0.0001823318,0.0000665127,0.00001724272,0.0003092194,0.00005575008,0.005534103],"category_scores_gemma":[0.000004355913,0.0001871626,0.0002411144,0.0001880252,0.0001036106,0.000215594,0.00002564977,0.000120092,0.001075795],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001358311,"about_ca_system_score_gemma":0.00001584137,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001609263,"about_ca_topic_score_gemma":0.000001546608,"domain_scores_codex":[0.9988108,0.00001609366,0.0005298405,0.0002728732,0.0000248662,0.0003455038],"domain_scores_gemma":[0.9992639,0.00001832443,0.0002779737,0.0002463946,0.00003744498,0.0001559124],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002745682,0.001843578,0.01453941,0.0001088023,0.0009576848,0.000004606281,0.01562023,0.00007118313,0.05733589,0.7177698,0.09562302,0.09585123],"study_design_scores_gemma":[0.001688135,0.0001798467,0.01881175,0.00001661634,0.00001490594,0.000001774716,0.0001399186,0.002830834,0.1375057,0.123816,0.7142316,0.0007629329],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7225703,0.004289894,0.0004043307,0.001989431,0.0004375353,0.0002044294,0.0003656863,0.00005510728,0.2696833],"genre_scores_gemma":[0.9658314,0.008771364,0.0003523073,0.02412699,0.0002891574,0.00002275575,0.000006723201,0.00003801082,0.0005613173],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6186086,"threshold_uncertainty_score":0.999702,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1950143140","doi":"","title":"Encouraging the use of generic medicines: implications for transition economies.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":190,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Competition (biology); Business; Payment; Generic drug; Promotion (chess); Public economics; Marketing; Market share; Demand side; Quality (philosophy); Industrial organization; Economics; Finance; Drug; Microeconomics; Medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.2495848310577156,"gpt":0.2688195064364776,"spread":0.019234675378762,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002638814,0.00008111093,0.0002093776,0.00009731288,0.00008294573,0.00003679878,0.0001593673,0.00004017077,0.0001090605],"category_scores_gemma":[0.00008545529,0.00007517795,0.0001126687,0.0001053908,0.00007263521,0.0001825864,0.00001348983,0.00005612262,0.00002624388],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005445692,"about_ca_system_score_gemma":0.000003602764,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004022333,"about_ca_topic_score_gemma":0.00000874863,"domain_scores_codex":[0.9991018,0.000006171852,0.0004548495,0.0001822254,0.000007629026,0.0002473054],"domain_scores_gemma":[0.9992931,0.0001785488,0.0001966547,0.0002360805,0.00001812248,0.00007752168],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002975247,0.0002523606,0.01133723,0.0001154407,0.0002942722,2.418383e-7,0.001699111,0.004183138,0.00002787526,0.5929715,0.1023286,0.2867605],"study_design_scores_gemma":[0.0007261123,0.0000139105,0.08024196,0.000002375136,0.00002342978,0.000003766759,0.00001975811,0.04672799,0.00007210079,0.03636394,0.8356065,0.0001981719],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4825684,0.01008411,0.04565641,0.3994387,0.002000246,0.006283408,0.003914129,0.0001544961,0.04990004],"genre_scores_gemma":[0.9916984,0.0008117791,0.0002284485,0.005531925,0.0002002923,0.001261111,0.00001124552,0.00001566552,0.000241125],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7332779,"threshold_uncertainty_score":0.3065668,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2045394072","doi":"10.1056/nejmsa003087","title":"Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme Inhibitors","year":2002,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":181,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Ministry of Health","funders":"Ministry of Health, British Columbia; Pfizer; Bristol-Myers Squibb; Deutsche Forschungsgemeinschaft; Agency for Healthcare Research and Quality; U.S. Department of Health and Human Services","keywords":"Medicine; Medical prescription; Cost sharing; Angiotensin-converting enzyme; Confidence interval; Christian ministry; Hazard ratio; Emergency medicine; Internal medicine; Pharmacology; Blood pressure","retraction":null,"screen_n_in":null,"score":{"opus":0.1048040640905049,"gpt":0.2984694581268024,"spread":0.1936653940362975,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008999673,0.0001224292,0.0007115671,0.0002722817,0.00003363033,0.000008051879,0.0001765384,0.00006454418,0.0004438819],"category_scores_gemma":[0.0006767318,0.00009859036,0.0001280321,0.0001112869,0.00006739284,0.0001179381,0.00001939408,0.0001916859,0.00001754125],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004268449,"about_ca_system_score_gemma":0.0000180014,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008955059,"about_ca_topic_score_gemma":0.00000674011,"domain_scores_codex":[0.9984352,0.00001129953,0.001168033,0.0001262402,0.00004737184,0.0002118532],"domain_scores_gemma":[0.9983433,0.0002866418,0.0009514435,0.0001314923,0.00008271199,0.0002044005],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006793668,0.0004624257,0.3113986,0.0003262955,0.001202583,0.00004987395,0.008406687,0.0005121068,0.003617042,0.1862495,0.2470817,0.2400138],"study_design_scores_gemma":[0.04713032,0.001547971,0.02316522,0.0002552846,0.0001079171,0.000144573,0.00008918616,0.006603487,0.002162066,0.05122969,0.8671482,0.0004160832],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9095268,0.01070528,0.003162681,0.05788892,0.002281799,0.0002661531,0.00005411822,0.00001421679,0.01610005],"genre_scores_gemma":[0.9946455,0.0007276735,0.0006756479,0.001832841,0.001612674,6.233625e-7,0.000001334582,0.00001492825,0.0004887542],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6200665,"threshold_uncertainty_score":0.4860196,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2135643683","doi":"10.1093/heapol/czh021","title":"Interactions between patent medicine vendors and customers in urban and rural Nigeria","year":2004,"lang":"en","type":"article","venue":"Health Policy and Planning","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":179,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Rockefeller Foundation; United States Agency for International Development","keywords":"Medical prescription; Quarter (Canadian coin); Business; Payment; Medicine; Position (finance); Marketing; Family medicine; Advertising; Nursing; History","retraction":null,"screen_n_in":null,"score":{"opus":0.1544873155491275,"gpt":0.3877181498090497,"spread":0.2332308342599221,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003623657,0.0001133907,0.0003480427,0.0003678186,0.0001352893,0.00002700225,0.00004004765,0.00004900449,0.00001478868],"category_scores_gemma":[0.00006614575,0.0001232683,0.00001464904,0.000126771,0.0000908175,0.0001250143,0.00003736431,0.0002112874,0.00001057394],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001144781,"about_ca_system_score_gemma":0.00003954873,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006218251,"about_ca_topic_score_gemma":0.00008872583,"domain_scores_codex":[0.9990022,0.00001563796,0.0004443393,0.0001936057,0.00001289142,0.0003313448],"domain_scores_gemma":[0.9993883,0.0001065817,0.0001484779,0.00007034961,0.000004011027,0.000282243],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00003600288,0.00002593595,0.7782604,0.000200738,0.0000401263,0.000006571346,0.01961507,0.0001528527,0.000006117175,0.1940315,0.0009710928,0.006653674],"study_design_scores_gemma":[0.003012164,0.00021461,0.7753092,0.0002883403,0.000004941307,0.00002904763,0.0009475666,0.0007092704,0.000005273743,0.04890763,0.170212,0.0003599837],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9626251,0.003923628,0.0000266535,0.02858503,0.0001385072,0.0001411318,0.0001309543,0.0000139555,0.004415059],"genre_scores_gemma":[0.9922407,0.001538265,0.00004330538,0.00568547,0.0004272759,0.000007592107,0.00001718995,0.00001049951,0.00002969892],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1692409,"threshold_uncertainty_score":0.9400176,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2082501248","doi":"10.1111/j.1528-1167.2007.01007.x","title":"Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug Classes","year":2007,"lang":"en","type":"article","venue":"Epilepsia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":178,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Group for Research in Decision Analysis; McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Lamotrigine; Clobazam; Pharmacy; Epilepsy; Adverse effect; Drug; Anticonvulsant; Generic drug; Brand names; Pharmacology; Family medicine; Psychiatry; Advertising","retraction":null,"screen_n_in":null,"score":{"opus":0.03838946776967719,"gpt":0.2809520929485794,"spread":0.2425626251789022,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008835395,0.0003333871,0.0009453936,0.0004175252,0.0001354553,0.00009285223,0.0004620755,0.00009322578,0.0003888639],"category_scores_gemma":[0.00002929512,0.0003446161,0.0001485732,0.0004930465,0.0000934355,0.0002028891,0.0001052961,0.0002607203,0.0005897651],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001293546,"about_ca_system_score_gemma":0.00004343292,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007305818,"about_ca_topic_score_gemma":0.0001122368,"domain_scores_codex":[0.9975497,0.0000292253,0.001136817,0.0005556407,0.00007183579,0.0006568274],"domain_scores_gemma":[0.9983324,0.0002714375,0.00052187,0.0004866948,0.00005641589,0.0003312076],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001718914,0.001349892,0.6326828,0.0004445661,0.001056157,0.00002618778,0.008531898,0.005616972,0.009189392,0.3069165,0.028442,0.004024685],"study_design_scores_gemma":[0.01017067,0.0006256063,0.5979829,0.0002797222,0.00009886632,0.00003129039,0.001176674,0.01902511,0.01648575,0.03176872,0.319395,0.002959725],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9659482,0.0004976469,0.007942528,0.001177708,0.0004341186,0.000369719,0.00009828155,0.00006330515,0.02346848],"genre_scores_gemma":[0.9915635,0.00006582194,0.003880984,0.003847357,0.0002656327,0.00001175475,0.00001926757,0.00007245458,0.0002732461],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.290953,"threshold_uncertainty_score":0.9999006,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3200608261","doi":"10.1016/s1470-2045(21)00463-0","title":"Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":171,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"Queen's University; World Health Organization","keywords":"Medicine; Snowball sampling; Essential medicines; Access to medicines; Cross-sectional study; Family medicine; Developing country; Descriptive statistics; Public health; Alternative medicine; Global health; Cancer; Environmental health; Nursing; Economic growth; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.2309375012748338,"gpt":0.4812587039765077,"spread":0.2503212027016739,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001665211,0.0001250905,0.0004890847,0.0001013762,0.00008520898,0.0001718621,0.0008062373,0.0001476036,0.003280643],"category_scores_gemma":[0.0003741306,0.0001189784,0.0000433597,0.0002278828,0.0001611586,0.0002671804,0.0002227937,0.0002566114,0.0001986219],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005284611,"about_ca_system_score_gemma":0.0002194531,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001890459,"about_ca_topic_score_gemma":0.0115584,"domain_scores_codex":[0.9984699,0.0001157134,0.0005776199,0.0004174659,0.00004141578,0.000377862],"domain_scores_gemma":[0.9989272,0.0003682482,0.0002104196,0.0002821682,0.00009297308,0.0001190342],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002232754,0.0001265628,0.967276,0.000007604515,0.0000648899,0.00001070202,0.0001589171,0.0005552324,0.00004687447,0.01460361,0.01655523,0.0003710804],"study_design_scores_gemma":[0.0009216608,0.00003576526,0.6191006,0.000001976308,0.000001518564,0.000005199554,0.00000631936,0.0006747015,0.0000746928,0.003476421,0.3756006,0.000100522],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9545745,0.0005508942,0.0001476658,0.0268897,0.002876766,0.0001711219,0.001897325,0.00002043572,0.01287164],"genre_scores_gemma":[0.9611549,0.002720609,0.00004782794,0.03393634,0.001384143,0.000106946,0.0001509912,0.00001618755,0.0004820094],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3590454,"threshold_uncertainty_score":0.9976305,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2127520342","doi":"10.1016/s0140-6736(02)11527-3","title":"The pharmaceutical industry as a medicines provider","year":2002,"lang":"en","type":"review","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":167,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Business; Intellectual property; Developing country; Drug prices; Essential drugs; Production (economics); Pharmaceutical industry; Essential medicines; International trade; Developed country; Access to medicines; Marginal cost; Industrial organization; Public economics; Commerce; Health care; Economic growth; Economics; Environmental health; Medicine; Health services; Pharmacology","retraction":null,"screen_n_in":null,"score":{"opus":0.2876269035881042,"gpt":0.4138744655755267,"spread":0.1262475619874224,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001309552,0.0003925264,0.001974614,0.00008237848,0.0003189127,0.0002420607,0.001547624,0.0004785537,0.001470835],"category_scores_gemma":[0.0003653033,0.0002216515,0.0004088784,0.0002673491,0.000328565,0.00007256273,0.0002380577,0.002072106,0.007163057],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001277957,"about_ca_system_score_gemma":0.0000767567,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003126846,"about_ca_topic_score_gemma":0.00000450601,"domain_scores_codex":[0.997667,0.00009137471,0.001022791,0.0004413161,0.00004969405,0.0007278493],"domain_scores_gemma":[0.9975477,0.0006835968,0.0005568967,0.001007029,0.00001420225,0.0001905977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000007979101,0.00002836218,0.00002001404,0.00125175,0.0002966815,0.0000065282,0.00007071264,7.632839e-7,6.238762e-9,0.2024777,0.2546573,0.5411823],"study_design_scores_gemma":[0.0003404446,0.00001628552,0.000003560074,0.0004138088,0.0001139891,0.0000486874,0.000006343055,0.0002768797,1.187488e-7,0.01587341,0.9826182,0.0002883466],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000004145736,0.8614521,0.000002328528,0.02345594,0.0008385346,0.0005454547,0.0002364005,0.00004272627,0.1134224],"genre_scores_gemma":[0.0000423036,0.9804286,0.000008311551,0.009170808,0.004932548,0.0001804212,0.00001305937,0.00006423602,0.005159749],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7279608,"threshold_uncertainty_score":0.999442,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2111436115","doi":"10.1111/j.1468-2354.2010.00615.x","title":"A DYNAMIC OLIGOPOLY STRUCTURAL MODEL FOR THE PRESCRIPTION DRUG MARKET AFTER PATENT EXPIRATION*","year":2010,"lang":"en","type":"article","venue":"International Economic Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":166,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"","keywords":"Oligopoly; Expiration date; Welfare; Nested logit; Microeconomics; Expiration; Economics; Prescription drug; Consumer welfare; Medical prescription; Market structure; Business; Industrial organization; Econometrics; Medicine; Market economy; Pharmacology","retraction":null,"screen_n_in":null,"score":{"opus":0.06074069930950473,"gpt":0.3125100873626672,"spread":0.2517693880531625,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006320802,0.0001821337,0.0003228536,0.00008017056,0.00009085632,0.0001458083,0.0005369772,0.00005848675,0.004605004],"category_scores_gemma":[0.00008094031,0.0001634959,0.000285523,0.00002533834,0.00006575972,0.0003756029,0.000083764,0.0002042146,0.0006521429],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001837791,"about_ca_system_score_gemma":0.00004436963,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007846757,"about_ca_topic_score_gemma":0.0002879838,"domain_scores_codex":[0.9985054,0.000009025643,0.0008472815,0.000380396,0.00002500658,0.0002329339],"domain_scores_gemma":[0.9990489,0.00009672801,0.0003730324,0.0003587668,0.00003507162,0.00008747012],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.0001752149,0.00006620227,0.003858349,0.0006030425,0.0005750634,0.000001355787,0.0003640479,0.003576922,0.00005366632,0.8494787,0.1076926,0.03355486],"study_design_scores_gemma":[0.0002697469,0.000004427458,0.001650229,0.00003422469,0.00001383569,0.000005382069,0.000001662412,0.6382266,0.000004181708,0.04352162,0.3161087,0.0001593858],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.3434102,0.1602363,0.03723515,0.2446669,0.03600052,0.009949024,0.01415598,0.0002615883,0.1540843],"genre_scores_gemma":[0.9578097,0.0215212,0.001304811,0.01178377,0.000364449,0.0008316826,0.00007986055,0.00003835925,0.006266119],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.805957,"threshold_uncertainty_score":0.9963049,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2105192804","doi":"10.1038/nchembio.1113","title":"A public-private partnership to unlock the untargeted kinome","year":2012,"lang":"en","type":"article","venue":"Nature Chemical Biology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":151,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Structural Genomics Consortium","funders":"Engineering and Physical Sciences Research Council; Cancer Research UK; Wellcome Trust","keywords":"Kinome; General partnership; Drug discovery; Business; Redundancy (engineering); Access to medicines; Kinase; Intellectual property; Computational biology; Computer science; Data science; Chemistry; Biology; Bioinformatics; Biochemistry; Finance","retraction":null,"screen_n_in":null,"score":{"opus":0.1039065332046124,"gpt":0.3186126969108578,"spread":0.2147061637062454,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006040714,0.0001846899,0.0003535753,0.0001122907,0.00008486302,0.00004027321,0.0005792358,0.0005368094,0.00068648],"category_scores_gemma":[0.0005380684,0.0001477986,0.0001385806,0.0003058198,0.0001187464,0.0001008306,0.0002280442,0.0007770772,0.001992537],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001123601,"about_ca_system_score_gemma":0.00001639059,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008624643,"about_ca_topic_score_gemma":0.000002198649,"domain_scores_codex":[0.9983541,0.00002403389,0.0004535899,0.0003488349,0.0000169471,0.0008025158],"domain_scores_gemma":[0.9988945,0.0001673957,0.0001340523,0.0003762439,0.00002071622,0.0004071081],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002259058,0.00006806511,0.02217526,0.000006528332,0.0000554101,2.148964e-7,0.0001654635,4.008248e-7,0.006730964,0.96372,0.006066483,0.0009885881],"study_design_scores_gemma":[0.0002619217,0.00001613484,0.002010837,0.000001782301,0.000003943753,0.000004046655,0.000006117747,0.00006889025,0.007019874,0.05417636,0.93619,0.0002400816],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8437263,0.008926798,0.0002313141,0.05814983,0.001277248,0.0003724228,0.0002495782,0.00009660244,0.08696994],"genre_scores_gemma":[0.970408,0.00005470995,0.000393368,0.02798096,0.0009422076,0.00003770235,0.00004430727,0.00002000055,0.0001188006],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9301235,"threshold_uncertainty_score":0.9987845,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1989028508","doi":"10.1503/cmaj.1041606","title":"Rofecoxib (Vioxx) voluntarily withdrawn from market","year":2004,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":143,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false},"ca_institutions":"","funders":"","keywords":"Medicine; Sepsis; SOFA score; Internal medicine; Pediatrics; Emergency medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.01529079297004724,"gpt":0.2289253502067974,"spread":0.2136345572367501,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001418062,0.0001424076,0.0003405141,0.0002259787,0.0002590305,0.0002211865,0.0003581245,0.0003792765,0.03395306],"category_scores_gemma":[0.0008847255,0.0001684897,0.000151395,0.0001630087,0.00004078747,0.0002404376,0.00002350623,0.0009058922,0.00349574],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002323787,"about_ca_system_score_gemma":0.00132313,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.02652818,"about_ca_topic_score_gemma":0.05148334,"domain_scores_codex":[0.9982324,0.00003000183,0.0007345036,0.000240706,0.0001499697,0.0006124089],"domain_scores_gemma":[0.9973662,0.0000940109,0.0003713359,0.0001369276,0.00006575417,0.00196577],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001904508,0.00009893808,0.2302432,0.000006490528,0.0004555529,0.000292518,0.0006789187,0.00008235759,0.000003061669,0.09837014,0.6605266,0.009223154],"study_design_scores_gemma":[0.001271163,0.00001977065,0.05316798,0.00001574085,0.000006395498,0.00003618931,0.00003393391,0.0005299852,0.000005266616,0.08353569,0.8611666,0.0002113079],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4107653,0.001994202,0.000954754,0.2909105,0.005249841,0.0002133438,0.001266393,0.00004840379,0.2885972],"genre_scores_gemma":[0.9085145,0.0005572481,0.0003790247,0.08560306,0.003363416,0.000007169039,0.00002589472,0.00003671436,0.001513003],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4977491,"threshold_uncertainty_score":0.9972802,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2015351537","doi":"10.1016/j.seizure.2005.12.010","title":"Are there potential problems with generic substitution of antiepileptic drugs?","year":2006,"lang":"en","type":"review","venue":"Seizure","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":143,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Dosing; Intensive care medicine; Adverse effect; Bioequivalence; Drug; Epilepsy; Risk analysis (engineering); Psychiatry; Pharmacology; Pharmacokinetics","retraction":null,"screen_n_in":null,"score":{"opus":0.07921406813877387,"gpt":0.2875214318073167,"spread":0.2083073636685429,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002325214,0.000411109,0.00187168,0.0002943942,0.00007296407,0.00006706815,0.0003739597,0.0003578263,0.0002250849],"category_scores_gemma":[0.00001218479,0.0003661943,0.0004535287,0.0003668541,0.0001350998,0.0001259028,0.00006378785,0.0003743018,0.0004386538],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001372496,"about_ca_system_score_gemma":0.00009945594,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000113613,"about_ca_topic_score_gemma":0.00001688991,"domain_scores_codex":[0.9979578,0.00002794379,0.001046716,0.0005373111,0.00004154064,0.0003887173],"domain_scores_gemma":[0.9975156,0.00002386391,0.001871224,0.0004508089,0.00003630172,0.0001022503],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007238354,0.001410605,0.002192632,0.1160078,0.003425021,0.0002058745,0.0002589446,0.003928035,0.00000145443,0.3378241,0.02916301,0.5055102],"study_design_scores_gemma":[0.0002890899,0.00003464107,0.000101564,0.001308338,0.0001599047,0.00002186286,0.000003758311,0.0002402791,5.364295e-7,0.001915665,0.9954761,0.0004482488],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000446045,0.9869019,0.0002334167,0.00006511329,0.0003274003,0.0005819746,0.001057124,0.0000313674,0.01035559],"genre_scores_gemma":[0.004776868,0.9934292,0.0001019563,0.0001151514,0.0004020866,0.00005591755,0.0002024287,0.00007964114,0.0008367203],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9663131,"threshold_uncertainty_score":0.999879,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2999258267","doi":"10.1136/bmj.l4627","title":"Pricing of pharmaceuticals is becoming a major challenge for health systems","year":2020,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":141,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"World Health Organization","keywords":"Drug pricing; Business; Market power; Healthcare system; Industrial organization; Risk analysis (engineering); Economics; Computer science; Health care; Marketing; Microeconomics; Actuarial science; Economic growth","retraction":null,"screen_n_in":null,"score":{"opus":0.2604861698715185,"gpt":0.4106091592542288,"spread":0.1501229893827103,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007308779,0.0001290256,0.0005909082,0.0000817279,0.00006565295,0.00003262547,0.0001991202,0.0000632427,0.0001849678],"category_scores_gemma":[0.0001545763,0.0001543062,0.0001556572,0.0001093109,0.00002872998,0.00009067673,0.0000592201,0.0001112649,0.0001839231],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000736425,"about_ca_system_score_gemma":0.00005044463,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008405182,"about_ca_topic_score_gemma":0.000001622794,"domain_scores_codex":[0.9982854,0.0000142194,0.0009992325,0.0003198642,0.00002352762,0.0003577533],"domain_scores_gemma":[0.9988886,0.0001446399,0.0005041148,0.000172636,0.00001630289,0.000273738],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003136782,0.0003080149,0.002766078,0.003666923,0.0005182966,0.000002931006,0.007626254,0.0003488098,0.0001781254,0.8333114,0.1394262,0.01153331],"study_design_scores_gemma":[0.001438447,0.0001597389,0.0001452043,0.00003206117,0.000009028598,0.000001833311,0.00008720397,0.1212423,0.000321973,0.005017082,0.8713037,0.0002414641],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.06521276,0.03350354,0.03139058,0.7690756,0.00211792,0.005725692,0.003677733,0.0001880466,0.08910818],"genre_scores_gemma":[0.9721454,0.001036103,0.0009796517,0.02487091,0.0007022742,0.00009699707,0.00000764354,0.00003712657,0.0001238515],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.9069327,"threshold_uncertainty_score":0.6292423,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2333798253","doi":"10.1097/00005650-200308000-00004","title":"Physician and Practice Characteristics Associated with the Early Utilization of New Prescription Drugs","year":2003,"lang":"en","type":"article","venue":"Medical Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":138,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"McGill University","funders":"","keywords":"Medical prescription; Medicine; MEDLINE; Intensive care medicine; Family medicine; Pharmacology; Political science","retraction":null,"screen_n_in":null,"score":{"opus":0.05608320431829633,"gpt":0.2916851483422187,"spread":0.2356019440239224,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003966077,0.0000745095,0.0001819992,0.00003073422,0.00005283702,0.00003188724,0.00008622909,0.00007616617,0.0001122719],"category_scores_gemma":[0.001091742,0.00006096569,0.00002649657,0.0001085691,0.00008025958,0.0001222261,0.00001786918,0.0001386791,0.0000179404],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003911688,"about_ca_system_score_gemma":0.00005592358,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009212975,"about_ca_topic_score_gemma":0.00001660972,"domain_scores_codex":[0.9993908,0.00004013582,0.0002363362,0.0001439709,0.00005509739,0.0001336933],"domain_scores_gemma":[0.9993322,0.0001581195,0.0002288764,0.0001130716,0.00004673074,0.000120957],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001731149,0.0002946475,0.05575431,0.0001442672,0.0003236684,0.000007497904,0.03008496,0.000009843909,0.00002917993,0.8446804,0.008715418,0.05978269],"study_design_scores_gemma":[0.00233881,0.0003050218,0.186144,0.00008589424,0.00008317285,0.000006334276,0.001992775,0.001872704,0.0001937078,0.007889638,0.7986754,0.0004125234],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9134624,0.002505537,0.001326311,0.007296339,0.000261363,0.0002740159,0.0001420215,0.00002321742,0.07470879],"genre_scores_gemma":[0.9963192,0.0002274596,0.00003654749,0.003147928,0.00007335278,0.000004232165,0.00001879354,0.0000108869,0.000161622],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8367907,"threshold_uncertainty_score":0.2486109,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3195451158","doi":"10.1080/00207543.2021.1950937","title":"Data analytics in pharmaceutical supply chains: state of the art, opportunities, and challenges","year":2021,"lang":"en","type":"article","venue":"International Journal of Production Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":129,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Polytechnique Montréal","funders":"","keywords":"Supply chain; Analytics; Scopus; Data science; Computer science; Supply chain management; Economic shortage; Big data; Data analysis; Knowledge management; Business; Data mining; MEDLINE; Marketing; Government (linguistics)","retraction":null,"screen_n_in":null,"score":{"opus":0.6582236673124685,"gpt":0.4682280153456835,"spread":0.189995651966785,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003230258,0.00005600416,0.0001851913,0.0003657532,0.00002976655,0.00005183585,0.0005797479,0.00002777743,0.0001672747],"category_scores_gemma":[0.001012351,0.00005153029,0.00004194221,0.0001565017,0.0001761845,0.0002909074,0.000382151,0.0004087209,0.000009597315],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009869372,"about_ca_system_score_gemma":0.0001849324,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001433724,"about_ca_topic_score_gemma":0.00005696702,"domain_scores_codex":[0.9987546,0.00009463966,0.0006352332,0.0001988329,0.0001590878,0.0001575593],"domain_scores_gemma":[0.9988896,0.0001113745,0.0002465174,0.0002619673,0.0004121825,0.00007833661],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005841157,0.001792656,0.04726668,0.0003498888,0.001343862,0.0003387327,0.002448472,0.002027264,0.001865177,0.6545435,0.04003689,0.2474027],"study_design_scores_gemma":[0.0007344346,0.00003925721,0.01635798,0.00007734008,0.000005321038,0.0001949564,0.0003034919,0.006197667,0.00224667,0.0343827,0.9393642,0.00009600012],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.471471,0.03045285,0.00008976555,0.4854151,0.002564251,0.0001914415,0.0007135522,0.000003777759,0.009098293],"genre_scores_gemma":[0.8829544,0.1148845,0.000141379,0.000306835,0.000446374,0.000001543047,0.000009385399,0.000009048657,0.001246489],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.8993273,"threshold_uncertainty_score":0.2101344,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3095635585","doi":"10.1136/bmjgh-2020-002640","title":"Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries","year":2020,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":128,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; McMaster University; Population Health Research Institute; Simon Fraser University","funders":"Faculty of Medicine and Health, University of Sydney; McMaster University; Hamilton Health Sciences","keywords":"Low and middle income countries; Income distribution; High income countries; Comprehensive income; Economics; Adjusted gross income; Business; Public economics; Gross income; Economic growth; Developing country; Inequality","retraction":null,"screen_n_in":null,"score":{"opus":0.04375054261232827,"gpt":0.3226200611086289,"spread":0.2788695184963006,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00185453,0.0002448028,0.001497946,0.00008164759,0.00008305166,0.00003924652,0.0001538959,0.0001205044,0.00004668921],"category_scores_gemma":[0.0003727436,0.0002489374,0.0001137832,0.0002274559,0.0003901772,0.0001777387,0.0002166722,0.0001695281,0.00001517643],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002031419,"about_ca_system_score_gemma":0.0001185112,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003347705,"about_ca_topic_score_gemma":0.0004767613,"domain_scores_codex":[0.9975266,0.00007488335,0.001262977,0.0006301178,0.00007305898,0.0004323344],"domain_scores_gemma":[0.9986031,0.0001780124,0.0003080227,0.0003855402,0.00003135355,0.0004939609],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00007009244,0.00003334272,0.9616125,0.001442022,0.00008324817,0.000002901263,0.0002235157,0.0000152426,1.254274e-7,0.03548053,0.00002724332,0.001009237],"study_design_scores_gemma":[0.001720244,0.0001733381,0.9729158,0.00008195497,0.00001161959,0.000009740867,0.00005278405,0.001553674,0.000003492026,0.02090006,0.002349566,0.0002277284],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9703519,0.01267548,0.00004295726,0.01445661,0.000180633,0.0006797059,0.001056325,0.0000231885,0.0005331851],"genre_scores_gemma":[0.9937916,0.003270023,0.0002826416,0.002533242,0.00008185858,0.00001751545,0.000005062325,0.0000123764,0.000005701036],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02343967,"threshold_uncertainty_score":0.9999963,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3011937804","doi":"10.1080/16549716.2019.1694745","title":"The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk","year":2020,"lang":"en","type":"review","venue":"Global Health Action","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":121,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"World Health Organization","keywords":"Transparency (behavior); Procurement; Accountability; Language change; Business; Corporate governance; Accounting; Public relations; Public economics; Economics; Finance; Marketing; Political science; Law","retraction":null,"screen_n_in":null,"score":{"opus":0.2756753538574691,"gpt":0.4388084882619515,"spread":0.1631331344044825,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003129181,0.0004030319,0.001605284,0.0001635039,0.0003450326,0.0001722807,0.0003449193,0.0003447772,0.00005632916],"category_scores_gemma":[0.0004966857,0.0003618178,0.0003247772,0.0006709471,0.0001770487,0.0003582214,0.00006297541,0.0009825575,0.00007098146],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001553205,"about_ca_system_score_gemma":0.0005283423,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001207912,"about_ca_topic_score_gemma":0.000384874,"domain_scores_codex":[0.9963136,0.000428148,0.00173807,0.0007912528,0.0001083332,0.0006205988],"domain_scores_gemma":[0.9969479,0.0001746081,0.00205756,0.0003742421,0.00006714602,0.0003785476],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004146203,0.0001179573,0.007771612,0.003760833,0.0001093802,2.837672e-7,0.00007057192,0.000002890706,5.472276e-8,0.008195653,0.0006054463,0.9793239],"study_design_scores_gemma":[0.0004855857,0.00008015087,0.004623059,0.0003056418,0.0001042193,0.000009703622,0.00002139582,0.0008246398,4.49295e-7,0.004106117,0.9891654,0.0002736425],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0009088553,0.9877748,0.0003339367,0.004209856,0.001105539,0.001602783,0.003149098,0.00003858232,0.0008765048],"genre_scores_gemma":[0.08858112,0.9107161,0.00003489309,0.0001886523,0.000256159,0.0001158755,0.00007349251,0.00002420568,0.000009528301],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.98856,"threshold_uncertainty_score":0.9998834,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4205704930","doi":"10.1038/s41574-021-00621-y","title":"Global accessibility of therapeutics for diabetes mellitus","year":2022,"lang":"en","type":"review","venue":"Nature Reviews Endocrinology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":118,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Sinai Health System; University of Toronto","funders":"NIHR Leicester Biomedical Research Centre; Madras Diabetes Research Foundation; Universidade Federal do Rio Grande do Sul; University of Toronto; National Institute for Health and Care Research","keywords":"Medicine; Diabetes mellitus; Intensive care medicine; Type 2 Diabetes Mellitus; Health care; Endocrinology; Economic growth","retraction":null,"screen_n_in":null,"score":{"opus":0.1931444438650594,"gpt":0.4247148174847424,"spread":0.231570373619683,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009198596,0.0005599316,0.005088961,0.000241811,0.00009500561,0.00002951342,0.001266037,0.0006970988,0.0008643844],"category_scores_gemma":[0.0003981072,0.0005260484,0.001833832,0.0004938404,0.0001475565,0.00007981282,0.0003514806,0.001059467,0.0001253548],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004524839,"about_ca_system_score_gemma":0.0001342095,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007843634,"about_ca_topic_score_gemma":0.000004760696,"domain_scores_codex":[0.9955632,0.0001802842,0.002507656,0.0009433166,0.00003348367,0.0007720218],"domain_scores_gemma":[0.9961916,0.0005324594,0.002168406,0.0009687941,0.00002656853,0.000112165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000003857974,0.00008062153,0.00008303723,0.0117817,0.0002879825,7.08472e-7,0.000004893233,1.739049e-7,1.136022e-8,0.1569897,0.001363714,0.8294036],"study_design_scores_gemma":[0.0002521978,0.00007172577,0.00001003731,0.0002824324,0.0003127705,0.000009038249,6.499362e-7,0.00001331056,5.136354e-7,0.02422964,0.9744047,0.0004130215],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000003347404,0.9838693,0.00003910061,0.0002569894,0.001523209,0.002014454,0.004018993,0.00002731598,0.00824729],"genre_scores_gemma":[0.00002222885,0.9960634,0.000376563,0.002021797,0.0002903186,0.0008275675,0.0002624704,0.00005469552,0.00008099146],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9730409,"threshold_uncertainty_score":0.9997191,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4256136035","doi":"10.1212/01.wnl.0000313154.55518.25","title":"Clinical consequences of generic substitution of lamotrigine for patients with epilepsy","year":2008,"lang":"en","type":"article","venue":"Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":117,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Lamotrigine; Medicine; Epilepsy; Gabapentin; Carbamazepine; Pharmacy; Psychiatry; Family medicine; Alternative medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1028178724892148,"gpt":0.3094421319751415,"spread":0.2066242594859267,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001637048,0.0000693101,0.0003721053,0.0000873626,0.00002710853,0.000001498019,0.0001157133,0.00008122752,0.00005322934],"category_scores_gemma":[0.00009376241,0.00006842098,0.00007872653,0.00007714502,0.0004620804,0.0000494982,0.00001632744,0.00007708296,0.00001714492],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000005165253,"about_ca_system_score_gemma":0.0000332888,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004897161,"about_ca_topic_score_gemma":0.00000538022,"domain_scores_codex":[0.9990317,0.00001559783,0.0005945288,0.0001989426,0.000012164,0.000147062],"domain_scores_gemma":[0.9992391,0.0001489266,0.0003792864,0.0001374572,0.00004595123,0.00004924834],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003299335,0.0001604053,0.9100612,0.00001794703,0.00002660986,9.09829e-7,0.00001487296,0.00009060667,0.00001655891,0.08892668,0.0001638502,0.0001904488],"study_design_scores_gemma":[0.003081276,0.002655817,0.912859,0.00000255157,0.00001192637,0.000007929801,2.672025e-7,0.001488994,0.0003321041,0.01134904,0.06805988,0.0001512132],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970552,0.0001692708,0.0004581686,0.0004478366,0.0002635757,0.0001699718,0.0001745906,0.000005770719,0.00125558],"genre_scores_gemma":[0.9981033,0.000342966,0.0004256402,0.001030354,0.00005594046,0.000009915082,0.00001221824,0.000007640443,0.00001205877],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07757764,"threshold_uncertainty_score":0.2790127,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2589088062","doi":"10.1016/j.healthpol.2017.02.002","title":"Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia","year":2017,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":114,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"University of British Columbia; Commonwealth Fund","keywords":"Confidentiality; Negotiation; Business; Statutory law; Discounting; Public health; Revenue; Public economics; Actuarial science; Marketing; Economics; Law; Finance; Medicine; Political science; Nursing","retraction":null,"screen_n_in":null,"score":{"opus":0.1511648610852986,"gpt":0.3988349864480218,"spread":0.2476701253627232,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001304797,0.000202385,0.0007580511,0.0003209878,0.000302136,0.0002728121,0.0002936671,0.00005105874,0.0000311414],"category_scores_gemma":[0.0002775793,0.0002020334,0.00002165586,0.0002713979,0.0006328549,0.0004449873,0.0001333637,0.0002512053,0.00001697163],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001567694,"about_ca_system_score_gemma":0.0006901307,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.105728,"about_ca_topic_score_gemma":0.006229547,"domain_scores_codex":[0.9976282,0.000161185,0.0009303114,0.0004717345,0.00005730435,0.0007512879],"domain_scores_gemma":[0.9978465,0.0001033869,0.0009647908,0.0003747673,0.00004603317,0.0006645065],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00009829481,0.0002010322,0.9212791,0.0006881289,0.00006396697,0.000005378671,0.01147097,0.00001513097,8.790367e-7,0.05690722,0.001141357,0.008128583],"study_design_scores_gemma":[0.001429859,0.0002835543,0.9211946,0.00003990058,0.000001626163,0.00001532667,0.0008075176,0.002497486,7.811279e-7,0.00005929658,0.07341211,0.0002579466],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9808309,0.00463524,0.0001203678,0.01139256,0.0001878873,0.0005054683,0.0008272925,0.00001213453,0.001488119],"genre_scores_gemma":[0.9892712,0.007643214,0.0000419926,0.002771186,0.0001107617,0.00004185344,0.00001955269,0.00002334005,0.00007690498],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09949845,"threshold_uncertainty_score":0.900227,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2043816730","doi":"10.1016/j.jval.2012.09.004","title":"What Is Wrong with Orphan Drug Policies?","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":110,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"","keywords":"Orphan drug; Business; Bioinformatics; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.1068436613679914,"gpt":0.3290383906729973,"spread":0.2221947293050059,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001073146,0.0001472307,0.0003791931,0.0002394414,0.00008107169,0.00009097789,0.0001780713,0.00005456715,0.0004051565],"category_scores_gemma":[0.00001616593,0.0001564841,0.00005316387,0.0002523516,0.00004930531,0.0007034296,0.00004791795,0.0002089074,0.0009743754],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003164004,"about_ca_system_score_gemma":0.00006716249,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007495855,"about_ca_topic_score_gemma":0.0000632816,"domain_scores_codex":[0.9983073,0.00003149608,0.0006052117,0.0002566353,0.00002688783,0.0007724392],"domain_scores_gemma":[0.9990151,0.00006948187,0.000253921,0.000286782,0.000007303305,0.0003674448],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002861868,0.0002535888,0.2657497,0.0001696373,0.0000339072,0.00000126383,0.009866913,0.0007592186,0.000001349211,0.7127651,0.007538591,0.002832166],"study_design_scores_gemma":[0.001431402,0.0001129177,0.05030961,0.0001409249,0.000003024417,0.00001557893,0.0005140444,0.01063614,0.0001075952,0.03066003,0.9054722,0.0005965818],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9178277,0.02178853,0.00007820145,0.04159255,0.001286749,0.0004060807,0.0001097274,0.00004089371,0.01686955],"genre_scores_gemma":[0.9731051,0.005590003,0.0003065683,0.01995041,0.0003581,0.0000188654,0.000005350656,0.0000321253,0.000633429],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8979335,"threshold_uncertainty_score":0.9998035,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2071885854","doi":"10.1136/bmj.38582.703866.ae","title":"“Breakthrough” drugs and growth in expenditure on prescription drugs in Canada","year":2005,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":107,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Vancouver Hospital and Health Sciences Centre; University of British Columbia","funders":"","keywords":"Medical prescription; Medicine; Drug industry; Computer science; Data science; Pharmacology; Biology; Biotechnology","retraction":null,"screen_n_in":null,"score":{"opus":0.03016981947161768,"gpt":0.2681968652973627,"spread":0.238027045825745,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002698464,0.0001110497,0.0002351363,0.0001495814,0.00002286399,0.00002842798,0.0001062032,0.00005934657,0.0002028122],"category_scores_gemma":[0.00003046608,0.000134329,0.0000240806,0.00008839662,0.00001754992,0.0001739738,0.00003545234,0.0001790644,0.0001210998],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005893602,"about_ca_system_score_gemma":0.00008300874,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.5468711,"about_ca_topic_score_gemma":0.4506807,"domain_scores_codex":[0.9989834,0.0000121765,0.0004467914,0.000271683,0.00002217765,0.000263741],"domain_scores_gemma":[0.9996333,0.00004260218,0.0001036996,0.0001310845,0.000003879684,0.00008543022],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","study_design_scores_codex":[0.0001297621,0.0002140207,0.3609263,0.00007045706,0.00003193579,0.00001520776,0.003861615,0.00132545,0.00001088542,0.5426027,0.07701775,0.01379397],"study_design_scores_gemma":[0.003151872,0.00004428352,0.5203196,0.00005230172,0.000002786409,0.000006206485,0.0003448078,0.02622458,0.0002778022,0.03588628,0.4129772,0.0007122779],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9076453,0.0006165239,0.00000418264,0.01646356,0.0002298438,0.0002210184,0.00008758602,0.000006897489,0.07472502],"genre_scores_gemma":[0.9942002,0.0003145864,0.00008161201,0.004851703,0.0002316888,0.00003178885,0.000007522506,0.00001276942,0.0002680941],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5067164,"threshold_uncertainty_score":0.559343,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1973148128","doi":"10.1208/s12248-009-9142-z","title":"Bioequivalence; Its History, Practice, and Future","year":2009,"lang":"en","type":"review","venue":"The AAPS Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":107,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Bioequivalence; Pharmaceutical industry; Business; Quality (philosophy); Management science; Risk analysis (engineering); Engineering ethics; Medicine; Pharmacology; Engineering","retraction":null,"screen_n_in":null,"score":{"opus":0.1733265012009086,"gpt":0.3625870007169042,"spread":0.1892604995159956,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001541188,0.0003300326,0.00122643,0.0002509514,0.0001976358,0.000194122,0.0006393759,0.0002471684,0.001041963],"category_scores_gemma":[0.0001418449,0.0002438758,0.0004106465,0.0001179618,0.00008942532,0.0003253666,0.00009435572,0.001324915,0.001182646],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004707537,"about_ca_system_score_gemma":0.000171417,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000004439148,"about_ca_topic_score_gemma":5.06935e-7,"domain_scores_codex":[0.9981434,0.0000933003,0.001019415,0.0003066049,0.00003887104,0.0003983599],"domain_scores_gemma":[0.9977693,0.0001722504,0.001439626,0.000334883,0.00003266429,0.0002512558],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000006205512,0.00003746163,6.725065e-7,0.0004984442,0.0001950333,0.00002168251,0.0001334193,2.079235e-7,2.797958e-8,0.1106851,0.06897479,0.819447],"study_design_scores_gemma":[0.0001639542,0.00004575476,0.000002811199,0.0002595308,0.0001819338,0.00134627,0.000009690049,0.00002061947,2.373322e-8,0.00702553,0.9906454,0.0002984867],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000001415455,0.9324461,0.00000719139,0.008181836,0.001582529,0.0001979928,0.00007915131,0.00001151053,0.05749228],"genre_scores_gemma":[0.000003894842,0.9899414,0.00009330038,0.004119157,0.004437767,0.000006640292,0.000004631532,0.00004030687,0.001352925],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9216706,"threshold_uncertainty_score":0.9998712,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2045226478","doi":"10.2165/00019053-200523120-00002","title":"Comment on ???The Economics of Follow-On Drug Research and Development: Trends in Entry Rates and the Timing of Development???","year":2005,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":104,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; Institute of Health Economics","funders":"","keywords":"Drug development; Drug; Pharmaceutical industry; Competition (biology); Drug class; Medicine; Marketing; Pharmacology; Business; Actuarial science","retraction":null,"screen_n_in":null,"score":{"opus":0.1738690385591195,"gpt":0.3662685802299175,"spread":0.1923995416707981,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00353841,0.0004730193,0.001187534,0.001036825,0.0002391895,0.00012665,0.0007622686,0.0002879849,0.00046115],"category_scores_gemma":[0.00005377648,0.000412589,0.0001328271,0.0001691405,0.00064278,0.0001401928,0.0003980222,0.00173168,0.0001130922],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004484579,"about_ca_system_score_gemma":0.0001437267,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001135428,"about_ca_topic_score_gemma":0.0000470021,"domain_scores_codex":[0.9964281,0.0001384857,0.001945837,0.0007343522,0.00005736765,0.0006958169],"domain_scores_gemma":[0.9964154,0.001993568,0.0009665794,0.0004763826,0.00003473847,0.000113301],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008249384,0.0003472282,0.003307086,0.0003948089,0.0009802178,0.000007226528,0.006003033,0.0003528596,0.00000480708,0.1211744,0.8376201,0.02898334],"study_design_scores_gemma":[0.00327224,0.00003680915,0.000305818,0.00006951567,0.00001238084,0.000002519693,0.0000702113,0.00309092,0.001594651,0.004661357,0.9864572,0.0004263696],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.3028453,0.002153085,0.000003168424,0.6674541,0.0004564308,0.0007538246,0.0003826385,0.00001182616,0.02593963],"genre_scores_gemma":[0.3911282,0.01120159,0.0004561233,0.5935367,0.001146297,0.0002943406,0.0001995932,0.0001810985,0.00185602],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.1488371,"threshold_uncertainty_score":0.9998326,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2173121992","doi":"10.1200/jco.2015.61.8736","title":"Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":102,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University","funders":"National Cancer Institute; National Institutes of Health; World Health Organization","keywords":"Medicine; Cancer; Intensive care medicine; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.6455804736146742,"gpt":0.6181926204129479,"spread":0.02738785320172632,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008823883,0.0003699843,0.008587727,0.0004407358,0.00004775298,0.00005192667,0.0005725897,0.0008220851,0.0001304561],"category_scores_gemma":[0.01165581,0.000265482,0.0007085595,0.0002741641,0.0002356006,0.0001645421,0.0002251561,0.001189894,0.00007390288],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003518424,"about_ca_system_score_gemma":0.002982333,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009296312,"about_ca_topic_score_gemma":0.0000470927,"domain_scores_codex":[0.9930001,0.0003566251,0.00574537,0.0004515769,0.00006951604,0.0003767843],"domain_scores_gemma":[0.9892389,0.003902925,0.005616418,0.000229459,0.0002350797,0.0007772174],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008537916,0.0001534975,0.0007211682,0.002555209,0.0004611718,0.00004361521,0.00005559047,0.000002309923,1.828909e-8,0.001963473,0.01243162,0.981527],"study_design_scores_gemma":[0.001126823,0.001064524,0.00007916171,0.0007558966,0.0006084512,0.00009761869,0.00001092167,0.000005884965,1.896786e-7,0.007720141,0.988259,0.0002713681],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001248007,0.9831463,0.0002105721,0.008661706,0.003124885,0.0003987745,0.0001409982,0.000009851754,0.004182111],"genre_scores_gemma":[0.00002991032,0.9902899,0.003904022,0.002861807,0.002479409,0.00002298143,0.000004198587,0.00004373077,0.0003639962],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9812556,"threshold_uncertainty_score":0.9999797,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2031692846","doi":"10.1211/ijpp.17.02.0002","title":"Consumers' views on generic medicines: A review of the literature","year":2009,"lang":"en","type":"review","venue":"International Journal of Pharmacy Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":102,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; MEDLINE; Reimbursement; Grey literature; Scopus; Health care; Seriousness; Family medicine; Public relations; Political science","retraction":null,"screen_n_in":null,"score":{"opus":0.1851946808773101,"gpt":0.4623296083132797,"spread":0.2771349274359696,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002106404,0.0003229056,0.001698467,0.0004169548,0.0000345798,0.00007642643,0.001568266,0.00009929134,0.0006400926],"category_scores_gemma":[0.002566754,0.000225561,0.001155451,0.0003820057,0.00006941357,0.0004566479,0.0001026141,0.00119336,0.0001962797],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002737149,"about_ca_system_score_gemma":0.0003280634,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008346272,"about_ca_topic_score_gemma":2.988227e-7,"domain_scores_codex":[0.9964472,0.0002292049,0.002688711,0.0002473721,0.0002027902,0.0001847084],"domain_scores_gemma":[0.9912642,0.0007764889,0.007045558,0.0003139774,0.0004585331,0.000141251],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001126886,0.0004768687,0.00001263294,0.01671569,0.002006211,0.000127592,0.000155005,0.000003940969,7.127849e-7,0.01675984,0.1039685,0.8596603],"study_design_scores_gemma":[0.0007654225,0.00004008379,0.000001632125,0.04276786,0.0004815966,0.0008688019,0.000002863823,0.00001038257,0.000002986873,0.0005080097,0.9543718,0.0001785471],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000001645603,0.9620614,0.00001595254,0.01615231,0.003215205,0.0003253838,0.000319245,0.000003361105,0.01790552],"genre_scores_gemma":[0.00002805365,0.9640335,0.0001486157,0.03436083,0.001160946,0.000007650233,0.00001699536,0.00002909231,0.0002142479],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8594818,"threshold_uncertainty_score":0.9198112,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2582303529","doi":"10.1371/journal.pmed.1002191","title":"What Is the Purpose of the Orphan Drug Act?","year":2017,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":102,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Orphan drug; Drug; Medicine; Pharmacology; Bioinformatics; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.09471316794752938,"gpt":0.3094459043501145,"spread":0.2147327364025851,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005239948,0.0001096773,0.0003247737,0.00004361889,0.0002875697,0.00008140069,0.0009944852,0.00004246777,0.001248586],"category_scores_gemma":[0.0002980271,0.00006417384,0.00009703098,0.00005320719,0.0004443094,0.0002700153,0.0001945678,0.0001827143,0.0002828518],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002853751,"about_ca_system_score_gemma":0.00001718724,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002018504,"about_ca_topic_score_gemma":0.00003235832,"domain_scores_codex":[0.9991233,0.00001244504,0.0004207594,0.0001961858,0.00004058342,0.0002066694],"domain_scores_gemma":[0.9982422,0.0001024216,0.0005104904,0.001039491,0.00002205168,0.00008337251],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007973539,0.0003939317,0.1039741,0.0002298343,0.0006288408,0.000005088643,0.0144676,0.000007712083,0.0008896018,0.6413989,0.2118791,0.02604561],"study_design_scores_gemma":[0.0014125,0.00004873912,0.03856111,0.0001749725,0.00004788362,0.000003578244,0.0002210554,0.002342865,0.005147679,0.1261446,0.825675,0.0002199983],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4818923,0.006324993,0.00001092146,0.4127496,0.002685612,0.0004643617,0.00008185986,0.00001397467,0.09577636],"genre_scores_gemma":[0.9789829,0.003609787,0.000006972942,0.01392416,0.0004887359,0.00001249108,0.000001268316,0.00001491764,0.002958806],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6137959,"threshold_uncertainty_score":0.9996644,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2121098095","doi":"10.1016/j.healthpol.2003.07.007","title":"The effect of generic competition on the price of brand-name drugs","year":2003,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":100,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; York University; University Health Network","funders":"","keywords":"Competition (biology); Formulary; Competitor analysis; Brand names; Business; Generic drug; Product (mathematics); Market share; Government (linguistics); Marketing; Economics; Advertising; Medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.04911101962320849,"gpt":0.333015503694424,"spread":0.2839044840712155,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001703563,0.0001119343,0.0003547111,0.0001124081,0.0001860046,0.00001675602,0.0002079219,0.00004579122,0.0001168306],"category_scores_gemma":[0.000319808,0.00007636485,0.0001158675,0.0002533346,0.0001240997,0.00003273205,0.00002289082,0.0001485973,0.0001789216],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001218409,"about_ca_system_score_gemma":0.0001007142,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007594198,"about_ca_topic_score_gemma":0.000009610133,"domain_scores_codex":[0.9986976,0.0001445068,0.000628919,0.0001570254,0.00003131271,0.0003406754],"domain_scores_gemma":[0.9983008,0.0007186122,0.000519437,0.0003425369,0.00001321507,0.0001053928],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002402465,0.0000226713,0.0008048723,0.00007915535,0.00001928384,3.876248e-8,0.000293237,0.00006008599,0.000006600424,0.9953755,0.001679186,0.00163535],"study_design_scores_gemma":[0.001183242,0.0006073209,0.00544596,0.00003160335,0.000003926918,0.000002645286,0.00002867857,0.001203836,0.001730021,0.04732605,0.9422706,0.0001661603],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7070923,0.004261339,0.0001408376,0.07069798,0.0004737247,0.0009380003,0.0002858679,0.00002102409,0.2160889],"genre_scores_gemma":[0.9905673,0.00205158,0.00001773181,0.006980978,0.0001277058,0.00002606693,0.00000249712,0.00001522419,0.0002109532],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9480494,"threshold_uncertainty_score":0.3114068,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2104400639","doi":"10.1503/cmaj.141564","title":"Estimated cost of universal public coverage of prescription drugs in Canada","year":2015,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":97,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":true},"ca_institutions":"Women's College Hospital; University of Toronto; University of British Columbia","funders":"Canadian Institutes of Health Research; Health Canada; Michael Smith Health Research BC","keywords":"Medical prescription; Government (linguistics); Prescription drug; Business; Public health; Public economics; Medicine; Economics; Pharmacology","retraction":null,"screen_n_in":null,"score":{"opus":0.04436535506075406,"gpt":0.2471488685197388,"spread":0.2027835134589847,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001335504,0.00006241114,0.0002694298,0.0002539832,0.0000258209,0.00002176944,0.0001862405,0.0001216056,0.000961635],"category_scores_gemma":[0.001398484,0.00007739296,0.00003960852,0.0002137044,0.00002229244,0.000167337,0.00001326769,0.0003255532,0.00002190632],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.00431747,"about_ca_system_score_gemma":0.007606572,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.8635032,"about_ca_topic_score_gemma":0.9515233,"domain_scores_codex":[0.9987949,0.00003869239,0.0006512326,0.0000888746,0.0001376058,0.0002887025],"domain_scores_gemma":[0.9982274,0.0000657335,0.0004544048,0.00006278209,0.0001674,0.001022347],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001242236,0.00003752088,0.8758592,0.00001201588,0.00007687633,0.00002905756,0.0004183027,0.0004648148,0.000001338191,0.03076747,0.08563035,0.006690621],"study_design_scores_gemma":[0.004230547,0.00005334259,0.2132283,0.00005379823,0.000008356472,0.00002838902,0.000671439,0.04861881,0.00002638536,0.009963197,0.7228078,0.000309632],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9276477,0.000424636,0.0001232925,0.03096177,0.001122824,0.0001281468,0.0006586282,0.000003367679,0.03892967],"genre_scores_gemma":[0.9969009,0.0001525996,0.00002002283,0.002735861,0.000108089,0.000001117329,0.00001246959,0.000006490861,0.00006251044],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6626309,"threshold_uncertainty_score":0.9999516,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2096918198","doi":"10.1212/01.wnl.0000349653.30398.e8","title":"CLINICAL CONSEQUENCES OF GENERIC SUBSTITUTION OF LAMOTRIGINE FOR PATIENTS WITH EPILEPSY","year":2009,"lang":"en","type":"letter","venue":"Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":95,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Lamotrigine; Epilepsy; Substitution (logic); Medicine; Clinical neurology; Psychiatry; Psychology; Neuroscience; Computer science","retraction":null,"screen_n_in":null,"score":{"opus":0.07985443588549204,"gpt":0.3069363065674907,"spread":0.2270818706819987,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002580923,0.0001893243,0.0009664024,0.000219736,0.00002262158,0.000006869034,0.0002866056,0.0005782798,0.00008055937],"category_scores_gemma":[0.0001112623,0.000190478,0.0002066673,0.00009538696,0.0004701189,0.00005041547,0.00002442844,0.0005433676,0.00002615088],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001368982,"about_ca_system_score_gemma":0.00006323382,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000052213,"about_ca_topic_score_gemma":0.000004571221,"domain_scores_codex":[0.9980478,0.00003909278,0.001153248,0.0004397086,0.00002522709,0.0002949833],"domain_scores_gemma":[0.9981253,0.000300528,0.001154154,0.0002956582,0.00007732031,0.00004705174],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001401242,0.0006143333,0.5613801,0.0005615036,0.0004178676,0.00002638615,0.00002754095,0.0001836035,0.000009298685,0.08730576,0.3454356,0.002636707],"study_design_scores_gemma":[0.001485919,0.002301119,0.03332271,0.000007562452,0.00003242789,0.000003008618,4.121268e-8,0.0002332323,0.00002049801,0.01403325,0.9483601,0.0002001817],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"commentary","genre_scores_codex":[0.7559682,0.000809714,0.0004671887,0.2343457,0.00156184,0.0009184125,0.002308999,0.00002224933,0.003597653],"genre_scores_gemma":[0.4708506,0.000681463,0.000540278,0.5262509,0.001189301,0.00003188365,0.0003430437,0.00004025787,0.00007225576],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.6029244,"threshold_uncertainty_score":0.7767466,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3056551509","doi":"10.3389/fmed.2020.00457","title":"The World Health Organization Global Benchmarking Tool an Instrument to Strengthen Medical Products Regulation and Promote Universal Health Coverage","year":2020,"lang":"en","type":"article","venue":"Frontiers in Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":94,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hamilton Health Sciences","funders":"World Health Organization","keywords":"Benchmarking; Business; Process management; Knowledge management; Engineering management; Computer science; Engineering; Marketing","retraction":null,"screen_n_in":null,"score":{"opus":0.03681927475095572,"gpt":0.2817846207367667,"spread":0.244965345985811,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001278895,0.0001171704,0.0003757243,0.00009649138,0.0001605554,0.00003582864,0.0001860077,0.00004102261,0.00008787553],"category_scores_gemma":[0.000483493,0.0001074383,0.00001068573,0.0006398018,0.00008051089,0.0001415989,0.00007205701,0.0001621675,0.000006363206],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004587548,"about_ca_system_score_gemma":0.0001619999,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000247506,"about_ca_topic_score_gemma":0.0002255243,"domain_scores_codex":[0.998619,0.00005998043,0.0005815984,0.0003682238,0.0000761378,0.0002950414],"domain_scores_gemma":[0.9991706,0.0000248219,0.000220841,0.0001598774,0.00001919228,0.0004046366],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001445666,0.00009209788,0.1697547,0.0001580243,0.0000682257,0.000004573417,0.006487474,0.0004741184,0.000002097435,0.2182395,0.1312298,0.4733448],"study_design_scores_gemma":[0.002969252,0.0009026607,0.1101115,0.0001586097,0.000006366157,0.000005424567,0.0004430422,0.1384977,0.000007990679,0.01609553,0.7304204,0.0003815779],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.187748,0.002285894,0.01775697,0.7882659,0.00141934,0.0009500063,0.00008223501,0.000044676,0.001446917],"genre_scores_gemma":[0.9609739,0.001985326,0.003162483,0.03289507,0.0007953384,0.000005878532,0.00009319084,0.00002018049,0.00006866425],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.7732259,"threshold_uncertainty_score":0.4381205,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2022778498","doi":"10.3386/w16431","title":"Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation","year":2010,"lang":"en","type":"report","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":93,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Competition (biology); Legislation; Loyalty; Business; Brand loyalty; Industrial organization; Advertising; Marketing; Commerce; Economics","retraction":null,"screen_n_in":null,"score":{"opus":0.3011440009757697,"gpt":0.4848980425436471,"spread":0.1837540415678774,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0099187,0.0002668215,0.0006107265,0.0009464907,0.0001190881,0.0002149794,0.0006347695,0.0004477655,0.0009896239],"category_scores_gemma":[0.0003734265,0.0002269468,0.0001527873,0.0002989971,0.0004051098,0.0002815811,0.0001786974,0.001815433,0.0002332746],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007729638,"about_ca_system_score_gemma":0.0005770102,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001492472,"about_ca_topic_score_gemma":0.001017869,"domain_scores_codex":[0.9968445,0.0002233203,0.001406099,0.0006540833,0.0002933476,0.0005786623],"domain_scores_gemma":[0.9975347,0.001308471,0.0004664815,0.0003978962,0.0001860301,0.0001064231],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004961145,0.0006559911,0.06276584,0.0005329545,0.000248519,0.00001825713,0.001855811,0.0006084749,0.00007626064,0.8914726,0.03642939,0.004839769],"study_design_scores_gemma":[0.001645374,0.00006256309,0.06268559,0.00008095067,0.00001173158,0.00004049169,0.00008637972,0.007489332,0.00002214638,0.3305649,0.5968689,0.0004416541],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"other","genre_gemma":"empirical","genre_scores_codex":[0.203413,0.01644581,0.00001316364,0.02286874,0.001363865,0.002166495,0.0008490604,0.00001206141,0.7528679],"genre_scores_gemma":[0.9775477,0.01977944,0.000024172,0.0007262548,0.0009377385,0.0002755059,0.0001943323,0.00003523316,0.0004796348],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.7741348,"threshold_uncertainty_score":0.9999236,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2890449704","doi":"10.1080/13571516.2011.584423","title":"Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation","year":2011,"lang":"en","type":"article","venue":"International Journal of the Economics of Business","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":92,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Fell; Quarter (Canadian coin); Legislation; Medical prescription; Brand loyalty; Market share; Generic drug; Competition (biology); Index (typography); Price index; Economics; Business; Advertising; Marketing; Medicine; Drug; Microeconomics","retraction":null,"screen_n_in":null,"score":{"opus":0.04733761495156,"gpt":0.266805689216466,"spread":0.219468074264906,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00104343,0.0001161391,0.000257419,0.0002138266,0.00003132964,0.00007935036,0.0007002375,0.00005758283,0.0001544518],"category_scores_gemma":[0.00005549002,0.00008003673,0.0001045851,0.0001302886,0.0001273738,0.0003961673,0.0001050672,0.0002468978,0.0000126594],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001036757,"about_ca_system_score_gemma":0.0000393551,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001394542,"about_ca_topic_score_gemma":0.00008413916,"domain_scores_codex":[0.9986832,0.00005362565,0.0009196657,0.0001396142,0.00004597066,0.000157949],"domain_scores_gemma":[0.9988647,0.0001369289,0.0007147808,0.0001686866,0.00008006522,0.00003487998],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00226593,0.001323679,0.6869956,0.0001059846,0.0005717805,0.0000344314,0.01220919,0.006645994,0.0002124553,0.2781725,0.001188334,0.01027412],"study_design_scores_gemma":[0.002148714,0.0000296246,0.9052274,0.00007180622,0.00001844849,0.0001148236,0.0001666934,0.006976108,0.0001438254,0.05776037,0.02714684,0.0001953449],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9806865,0.001463865,0.0001547959,0.01186781,0.00124156,0.0001593167,0.00005458673,0.000001341665,0.004370173],"genre_scores_gemma":[0.9937262,0.003649363,0.00006172311,0.002255565,0.0002722326,0.000007086928,0.000002052151,0.00001018309,0.00001558794],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2204121,"threshold_uncertainty_score":0.3263803,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1561889056","doi":"10.3386/w20799","title":"Intellectual Property Rights and Access to Innovation: Evidence from TRIPS","year":2014,"lang":"en","type":"preprint","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":90,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"TRIPS architecture; Intellectual property; Business; Competition (biology); TRIPS Agreement; Price premium; Product (mathematics); International economics; International trade; Drug prices; Industrial organization; Economics; Public economics; Microeconomics","retraction":null,"screen_n_in":null,"score":{"opus":0.6725693421532669,"gpt":0.5429627906360296,"spread":0.1296065515172373,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004212121,0.000282994,0.0008240685,0.001729231,0.0001589709,0.0004717225,0.001309162,0.0003883696,0.001825924],"category_scores_gemma":[0.003029735,0.000277422,0.0001148805,0.0003700779,0.0002754778,0.0004169274,0.001807328,0.0009942069,0.00128946],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008234734,"about_ca_system_score_gemma":0.0004724846,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004973866,"about_ca_topic_score_gemma":0.0001629602,"domain_scores_codex":[0.9966642,0.0001040639,0.001522907,0.001105007,0.0001527066,0.0004510627],"domain_scores_gemma":[0.996278,0.001969845,0.0004966456,0.0005225207,0.0005065423,0.000226372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.0002426402,0.00009798103,0.002692662,0.0001667331,0.0002658782,9.658222e-7,0.0006721247,0.003014621,0.0000722234,0.8679469,0.1229017,0.001925612],"study_design_scores_gemma":[0.0003708591,0.0000733705,0.001092685,0.0001371334,0.00000421914,0.000001150256,0.000004833289,0.02033078,0.0005951683,0.9121141,0.06494334,0.000332348],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.697459,0.00276916,0.001002778,0.03041198,0.001655042,0.00247448,0.001699264,0.00005301798,0.2624753],"genre_scores_gemma":[0.9950933,0.0005299425,0.0005940266,0.0009285723,0.001060618,0.0002027742,0.0001733354,0.00003653267,0.001380894],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2976343,"threshold_uncertainty_score":0.9999678,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2082560103","doi":"10.1002/hec.698","title":"The importance of being first: evidence from Canadian generic pharmaceuticals","year":2002,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":89,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Calgary","funders":"Health Canada","keywords":"Competitor analysis; Market share; Generic drug; Business; Drug industry; Drug approval; Industrial organization; Economics; Marketing; Public economics; Drug; Medicine; Pharmacology; Engineering","retraction":null,"screen_n_in":null,"score":{"opus":0.1884296525869112,"gpt":0.334590399991603,"spread":0.1461607474046918,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009413891,0.0002097977,0.0005632484,0.0001466336,0.0004655501,0.00009926248,0.000580887,0.0001063779,0.001454166],"category_scores_gemma":[0.0001867756,0.0002267188,0.0001553847,0.0001542704,0.0001486446,0.0002645878,0.00007865633,0.0002593151,0.001048206],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006907353,"about_ca_system_score_gemma":0.000162861,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.03290598,"about_ca_topic_score_gemma":0.07718357,"domain_scores_codex":[0.9972066,0.0000272098,0.001435106,0.0004870693,0.00002011455,0.00082392],"domain_scores_gemma":[0.9974738,0.0004954539,0.0006934401,0.0006134232,0.00002213504,0.0007017368],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003988609,0.0001166062,0.4141025,0.0001646335,0.0002723947,0.000005644316,0.002478922,0.001473116,0.000005053063,0.495798,0.06238314,0.02316011],"study_design_scores_gemma":[0.000408333,0.00004315225,0.01023251,0.00002976795,0.000006130011,0.000003442698,0.0000286887,0.09967349,0.00004669917,0.02975298,0.8594491,0.0003257208],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6854638,0.08356744,0.000151572,0.1949498,0.002034736,0.0008722385,0.001251383,0.00005637818,0.03165261],"genre_scores_gemma":[0.898099,0.08282002,0.00045404,0.01784369,0.0003608866,0.00004207764,0.00001086353,0.00004612082,0.000323311],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.797066,"threshold_uncertainty_score":0.9997296,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2046647352","doi":"10.1097/mlr.0b013e31818af850","title":"Is There a Relationship Between Patient Beliefs or Communication About Generic Drugs and Medication Utilization?","year":2009,"lang":"en","type":"article","venue":"Medical Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":88,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Institute on Aging; Canadian Institutes of Health Research","keywords":"Pharmacy; Scale (ratio); Medical prescription; Medicine; Generic drug; Family medicine; Health communication; Drug; Actuarial science; Psychology; Nursing; Business; Pharmacology","retraction":null,"screen_n_in":null,"score":{"opus":0.1341146675802448,"gpt":0.3455821168426299,"spread":0.2114674492623851,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000328502,0.000122434,0.0002477171,0.0001089555,0.0001868361,0.00004859408,0.0002411269,0.0001945836,0.0009547992],"category_scores_gemma":[0.0003801069,0.0001186737,0.00005079319,0.0001909847,0.00009416531,0.0001270033,0.00006224902,0.0002450372,0.0001637806],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009943398,"about_ca_system_score_gemma":0.00006150967,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006077423,"about_ca_topic_score_gemma":0.00001802421,"domain_scores_codex":[0.9988372,0.00003785733,0.0005630192,0.0002749592,0.00008626137,0.000200743],"domain_scores_gemma":[0.9989404,0.0001937382,0.0002052716,0.00033929,0.00003637238,0.00028494],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00002148871,0.00008821399,0.595376,0.00007811483,0.00003939135,0.000002185309,0.01633965,0.000004810406,4.445282e-7,0.1718981,0.008440377,0.2077112],"study_design_scores_gemma":[0.0007640566,0.0001113373,0.7642189,0.0000595865,0.00001467713,0.00000285985,0.0003742541,0.001810524,0.00002093729,0.03196026,0.200403,0.0002595559],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8816594,0.03082979,0.001209892,0.04834131,0.0001822734,0.0004548827,0.0003443769,0.00009423022,0.03688385],"genre_scores_gemma":[0.9891664,0.00221619,0.0002253483,0.007939878,0.0001412637,0.00001902195,0.0001716796,0.00001331696,0.0001069433],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2074517,"threshold_uncertainty_score":0.9999585,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2060894663","doi":"10.1038/clpt.2014.145","title":"Accelerated Access to Innovative Medicines for Patients in Need","year":2014,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":87,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Canada; Institut National d'Excellence en Santé et en Services Sociaux","funders":"Innovative Medicines Initiative; National Comprehensive Cancer Network; European Federation of Pharmaceutical Industries and Associations; Bill and Melinda Gates Foundation","keywords":"Clinical pharmacology; Variety (cybernetics); Access to medicines; Business; Health care; Medicine; Pharmacology; Economic growth; Computer science; Economics; Nursing; Public health","retraction":null,"screen_n_in":null,"score":{"opus":0.2719753222378785,"gpt":0.4731631481498151,"spread":0.2011878259119367,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001279842,0.000220515,0.0007312981,0.0003089916,0.00007252107,0.00005187353,0.0006267352,0.0002344269,0.0002830315],"category_scores_gemma":[0.0002207972,0.0002356165,0.0001147394,0.0006055627,0.000159817,0.0001748103,0.0001620974,0.000388023,0.0002781101],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008949466,"about_ca_system_score_gemma":0.00004365102,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001728171,"about_ca_topic_score_gemma":0.00001193222,"domain_scores_codex":[0.9973946,0.00008554092,0.001441265,0.0005360154,0.00002598371,0.0005166369],"domain_scores_gemma":[0.9980677,0.0009785938,0.000361914,0.0002086038,0.0001628494,0.0002203555],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0009943907,0.00183768,0.8510924,0.00004667458,0.0005318397,0.00000124083,0.0003828047,0.0001737468,0.0001562769,0.01287281,0.1158807,0.01602946],"study_design_scores_gemma":[0.007791516,0.0007416323,0.2117404,0.000009115063,0.00004208693,2.35213e-7,0.000008884736,0.0136292,0.0003325532,0.01924335,0.7460267,0.0004342835],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9314828,0.0001136282,0.00199213,0.05626208,0.004006779,0.001286326,0.0001678716,0.00005149665,0.004636919],"genre_scores_gemma":[0.6852491,0.0002340786,0.0002487258,0.3133848,0.0006301604,0.0001198829,0.00002966296,0.00003347664,0.00007012796],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.639352,"threshold_uncertainty_score":0.9608164,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1743375347","doi":"10.1111/j.1755-5949.2010.00210.x","title":"Switching from Brand‐Name to Generic Psychotropic Medications: A Literature Review","year":2010,"lang":"en","type":"review","venue":"CNS Neuroscience & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":84,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Lamotrigine; Venlafaxine; Tolerability; Medicine; Psychiatry; Topiramate; Quetiapine; Clonazepam; Cobicistat; Pharmacology; Psychology; Adverse effect; Anxiety; Epilepsy; Schizophrenia (object-oriented programming); Antidepressant","retraction":null,"screen_n_in":null,"score":{"opus":0.1606504007618799,"gpt":0.3863121722456307,"spread":0.2256617714837508,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005398974,0.0006022229,0.001929164,0.0004220479,0.0002484676,0.000411793,0.00189116,0.0004033586,0.0001963241],"category_scores_gemma":[0.0001067757,0.0005687576,0.0005739782,0.001343763,0.000130585,0.000245348,0.0001956487,0.001370393,0.001096974],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001130451,"about_ca_system_score_gemma":0.0001648708,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000009080271,"about_ca_topic_score_gemma":0.000007077122,"domain_scores_codex":[0.9963631,0.00007399669,0.001503506,0.001290353,0.00009931983,0.0006696933],"domain_scores_gemma":[0.9971212,0.0001552079,0.000854113,0.001371804,0.00003114982,0.0004665249],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000002211722,0.0001137371,0.00001858376,0.003197286,0.00005823954,0.000009066765,0.000195427,0.000001303875,0.00002187426,0.009559663,0.001593234,0.9852294],"study_design_scores_gemma":[0.0001155596,0.00003466191,0.00002203742,0.00570492,0.0001874269,0.00002523582,6.236113e-7,0.0001678233,6.920823e-7,0.003490916,0.9896769,0.0005732019],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001875735,0.9890103,0.0009132288,0.003646801,0.002755397,0.001013319,0.001056997,0.00006983573,0.001515404],"genre_scores_gemma":[0.00001564218,0.9287732,0.0003939924,0.06959752,0.0006060144,0.0001854065,0.00007613335,0.00009162229,0.0002605302],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9880837,"threshold_uncertainty_score":0.9996808,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}